Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
Sera Prognostics insider Paul Kearney filed a Form 144 to sell 6,460 Class A common shares of SERA, representing an aggregate market value of $16,410. The securities were acquired by restricted stock unit vesting on 08/08/2025 and the proposed sale is also dated 08/08/2025. The sale is to be executed through Morgan Stanley Smith Barney. The filing reports 38,061,868 shares outstanding for the issuer, giving context to the size of this sale.
The form also discloses two recent sales by the same person: 7,089 shares on 05/08/2025 (gross proceeds $17,315) and 1,311 shares on 06/10/2025 (gross proceeds $1,946). The notice includes the standard insider representation that no undisclosed material adverse information is known to the seller.
Form 144 filing reports a proposed sale of 6,447 Class A Common shares of Sera Prognostics (SERA) through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $16,377. The record lists 38,061,868 shares outstanding. The securities were acquired via restricted stock unit vesting from the issuer on 08/08/2025, with the same date shown as the approximate sale date.
The filing also discloses sales in the past three months by Benjamin Jackson: 7,084 shares sold on 05/08/2025 for $17,303 and 965 shares sold on 06/10/2025 for $1,433. Several standard filer contact fields (CIK/CCC and named account fields) are not populated in the provided content.
Sera Prognostics submitted a Form 144 notice proposing the sale of 5,962 Class A common shares, with an aggregate market value of $15,145. The filing reports 38,061,868 shares outstanding, placing the proposed sale in the context of the company's issued share base.
The shares are scheduled for sale on 08/08/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The securities were acquired by Restricted Stock Unit vesting from the issuer on 08/08/2025, with payment noted as not applicable.
The filing also discloses prior sales by Robert Harrison: 6,551 shares on 05/08/2025 for $16,001 and 667 shares on 06/10/2025 for $990. The signer represents no knowledge of undisclosed material adverse information.
Sera Prognostics' Form 144 shows a proposed sale of 7,094 Class A Common shares through Morgan Stanley Smith Barney on 08/08/2025. The filing states these shares were acquired by Restricted Stock Unit vesting on 08/08/2025 and lists an aggregate market value of 18,021 with 38,061,868 shares outstanding. The filing also discloses sales in the past three months: 5,132 shares on 05/08/2025 (gross proceeds 12,535) and 1,439 shares on 06/10/2025 (gross proceeds 2,136), totaling 6,571 shares sold for 14,671 gross proceeds. The notice includes the required representation that the seller does not possess undisclosed material adverse information.
Sera Prognostics reported an insider notice to sell 5,800 Class A common shares with an aggregate market value of $14,734, planned on 08/08/2025 on NASDAQ. The shares were acquired the same day through Restricted Stock Unit vesting, and the sale is listed with Morgan Stanley Smith Barney LLC. The proposed sale equals approximately 0.015% of the 38,061,868 outstanding shares. In the prior three months the filer sold 6,374; 5,735; and 945 shares for combined gross proceeds of $25,196. The filer certifies no known material nonpublic information.
Sera Prognostics (SERA) Form 4: Director Mansoor Raza Mirza reported the automatic sale of 225 Class A common shares on 08/05/2025 at $2.50 per share ($563 total value). The shares were sold exclusively to satisfy tax-withholding obligations triggered by the vesting of restricted stock units; the transaction was executed under the company’s mandatory “sell-to-cover” program and was not discretionary. Following the sale, Mirza’s direct beneficial ownership stands at 58,702 shares. No derivative securities were involved and no changes were made to option or RSU positions.
The filing reflects a routine administrative sell-to-cover with de minimis dollar value relative to company market capitalization and Mirza’s remaining stake. There are no indications of broader insider sentiment, strategic shifts, or liquidity concerns.
Sera Prognostics, Inc. (SERA) submitted a Form 144 notice covering the planned sale of 225 Class A common shares through Morgan Stanley Smith Barney on 05 Aug 2025. At the indicated aggregate market value of $563, the transaction is de-minimis relative to the company’s 37,672,784 shares outstanding (≈0.0006%).
The seller—identified in subsequent tables as Mansoor Raza Mirza—previously sold 447 shares over the past three months for total gross proceeds of $980. The shares to be sold were acquired via RSU vesting on the planned sale date, implying the disposal is likely routine compensation-related rather than a directional view on the business. The filer affirms possession of no undisclosed material information, satisfying Rule 144 requirements.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. have filed a Schedule 13G disclosing a passive ownership stake in Sera Prognostics (SERA).
- Shares owned: 2,227,367 Class A common shares.
- Ownership percentage: 6.07% of the outstanding class as of 30 Jun 2025.
- Voting & dispositive power: 0 shares held with sole power; all 2,227,367 shares held with shared voting and dispositive power by both reporting entities.
- Reporting parties: Aberdeen Group plc (UK parent, classified as a Holding Company – “HC”) and abrdn Inc. (US subsidiary, classified as Corporation & Investment Adviser – “CO, IA”).
- Intent: Certification states the position is held in the ordinary course of business and is not intended to influence or control the issuer.
- Structure: Aberdeen Group plc → abrdn Holdings Ltd. → abrdn Inc.; the U.S. adviser holds the shares for underlying clients.
The filing indicates that a sizable institutional investor has surpassed the 5 % threshold, triggering disclosure under Rule 13d-1(b). No changes to company control or strategic direction are signaled.